Related Experiment Video
Updated: May 4, 2026
06:45
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
3.2K
Levodopa fractionation in Parkinson's disease
Dag Nyholm1, Victoria Stepien1
1Department of Neuroscience, Neurology, Uppsala University, Sweden.
Journal of Parkinson'S Disease
|January 9, 2014
Summary
Fractionating levodopa dosage into more than four doses daily is common practice for Parkinson
Area of Science:
- Neuroscience
- Clinical Pharmacology
- Pharmacoepidemiology
Background:
- Managing Parkinson's disease (PD) motor fluctuations often involves adjusting levodopa dosage.
- Levodopa dose fractionation is a key strategy, but its real-world application in clinical practice remains unclear.
Purpose of the Study:
- To investigate the utilization of anti-Parkinsonian medications.
- Specifically, to determine how daily levodopa doses are fractionated (defined as >4 doses/day) in routine clinical practice.
Main Methods:
- A retrospective pharmacoepidemiological study was conducted at Uppsala University Hospital.
- Medical records of 175 Parkinson's disease patients with at least 4 years of disease duration were reviewed.
- Kaplan-Meier analysis was used to calculate time to dose fractionation, dyskinesias, and hallucinations.
Main Results:
- Levodopa dose fractionation (>4 doses/day) was employed in 85% of Parkinson's disease patients.
- The median time to initiating dose fractionation was 5.0 years after diagnosis.
- Patients who developed dyskinesias had a significantly earlier age of Parkinson's disease onset.
Conclusions:
- Fractionation of levodopa into more than four daily doses is a frequent clinical strategy for Parkinson's disease.
- This practice typically begins around the 5-year mark, coinciding with the expected onset of levodopa response "wearing-off".
- Individualized and frequent adjustments to levodopa dosage, starting early in treatment, are crucial for effective Parkinson's disease management.
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
01:24Parkinson Disease ll: Pathophysiology
28
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
28
01:24Parkinson Disease l: Introduction
28
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of...
28
01:15Parkinson's Disease: Overview
2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
01:25Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
394
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
394
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
928
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
928